Avivit Peer
8 Haaliya Street
Haifa, HA, Israel
Haifa, HA, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
De-Escalation Therapy in Metastatic Prostate Cancer: A Retrospective Study on Intermittent ADT and ARPI Combination Treatment.
Journal: Clinical genitourinary cancer
Published: May 05, 2026
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.
Journal: Future oncology (London, England)
Published: February 24, 2026
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 07, 2025
Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall Survival.
Journal: Targeted oncology
Published: April 18, 2025
Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults.
Journal: Vaccine
Published: February 05, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 23, 2025
Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1.
Journal: The Journal of infectious diseases
Published: November 13, 2024
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Journal: Urologic oncology
Published: June 26, 2024
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer.
Journal: The oncologist
Published: May 13, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Journal: Prostate cancer and prostatic diseases
Published: February 28, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 16, 2024
Last Updated: 09/26/2026